Eficacia de dutasteride en hiperplasia prostática benigna en el Hospital regional Vicente Corral Moscoso. Cuenca, 2011-2012

Abstract

Objective: To determine the efficacy of Dutasteride´s treatment for 6 months for a group of patients diagnosed with Benign Prostatic Hyperplasia in “Vicente Corral Moscoso” Regional Hospital.

Methods and materials: It presents a descriptive study completed in “Vicente Corral Moscoso” Regional Hospital in Cuenca’s city. The size of the sample was 60 patients from a universe of 225, it was chosen by convenience and the selected patients were diagnosed of moderate and severe benign prostatic hyperplasia taking the following parameters: ultrasound and blood measured PSA (until 6ng/ml.). We interview our group of patients the “International Prostate Symptom Score” admitted by the World Health Organization.All patients received single therapy with Dutasteride (5 mg QD) for 6 months. The information was analyzed with Microsoft Excel and Epi-Info. In our study we apply statistics measures with duplicate entries and inferential analysis, Chi 2, confidence interval, mean difference, etc.

Results: The average age of patients was 69.72 ± 8.92 years, in relation to the civil status 66.67 % were married. The Prostate Specific Antigen average at the beginning was: 4.07ng and wtih 6 months of treatment it value decreased to: 3.38ng with a Z score of 6.55 (p < 0.001). The variation in prostate weight was not statistically significant with a Z = 0 (p > 0.05) score after a 6-month treatment. With the following symptoms vesical tenesmus (Chi2: 5.71), polaquiria (Chi2:8.57) and intermittent urinary flow (Chi2:8.57) a significant difference was obtained after a 3-month treatment. Between the starting point and 6 months of therapy there was a improvement statistically significant for: polaquiria (Chi2:9.73), intermittent urinary flow (Chi2:10.91) and nycturia (Chi2:8.09) , excluding mictional urgency, which did not reach statistically significance. On the improvement between 3 and 6 months of treatment, no significant difference was found in any symptoms of the scale.

Conclusion: After a 6-months therapy with Dutasteride isn’t safe to take therapeutic decisions because of the statistically lower improvements to the end of this period of time. We consider recommendable larger studies in a longer period of time for accurate results and bearing in mind collateral effects.

KEYWORDS: BENIGN PROSTATIC HYPERPLASIA, DUTASTERIDE, PROSTATE SPECIFIC ANTIGEN, EFFECTIVENESS OF TREATMENT, SYMPTOMS ASSESSMENT.